Advertisement

Topics

OMEICOS Therapeutics Company Profile

22:37 EDT 18th June 2018 | BioPortfolio

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular and other diseases. Epoxyeicosanoids, as a newly described class of bioactive lipid mediators, activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. OMEICOS’ technology is based on ground-breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders, Dr. Wolf-Hagen Schunck, Prof. John. R. Falck, Prof. Dominik Müller and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com.


News Articles [776 Associated News Articles listed on BioPortfolio]

Omeicos Opthalmics names first CEO

Omeicos Opthalmics, a subsidiary of German biotech Omeicos Therapeutics, has named Alexander Gebauer…

Appointments: Basliea, BenevolentAI, OMEICOS, Recursion, Takeda UK And Bone Therapeutics Announce New Hires

New appointments have been announced this week by Basilea, BenevolentAI, OMEICOS Therapeutics, Pharnext, Recursion Pharmaceuticals, Sonde Health, Takeda UK, Bone...   

Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics

-- Appointment marks further progress in ramping-up US-based subsidiary as validation of OMEICOS’ lead compound also progresses through clinical trials in atrial fibrillation --...

Alexander Gebauer joins OMEICOS

IPO Update: Returns Halved As Two More Biopharma Firms Go Public In April

Only two drug developers launched offerings in April, but it remains to be seen how many biopharma companies will go...   

IPO Update: Returns Halved As Two Biopharmas Go Public In April; Unity Is May's First

Only two drug developers launched offerings in April and the average 2018 IPO return was just 9% – half the...    

Deaths In Esperion's Long-Term Bempedoic Acid Trial Spur Fears Of Commercial Delay

On top of concerns about safety, which could present regulatory hurdles, bempedoic acid is likely to face a tougher competitive...    

OMEICOS Therapeutics GmbH Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13032018] Prices from USD $250

SummaryOMEICOS Therapeutics GmbH OMEICOS is a biopharmaceutical company that develops small molecule therapeutics. The company utilizes its proprietary technology of the body's own omega3 fatty acid m...

PubMed Articles [411 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1236 Associated Companies listed on BioPortfolio]

OMEICOS Therapeutics GmbH

OMEICOS Therapeutics is a spin-off company from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synt...

OMEICOS Therapeutics

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthe...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "OMEICOS Therapeutics" on BioPortfolio

We have published hundreds of OMEICOS Therapeutics news stories on BioPortfolio along with dozens of OMEICOS Therapeutics Clinical Trials and PubMed Articles about OMEICOS Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OMEICOS Therapeutics Companies in our database. You can also find out about relevant OMEICOS Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record